glp-1 asthma Drugs May Cut Flare-Ups in People With Overweight or Obesity GLP-1 receptor agonist use linked

Diabetes Investig., vol

More recently, the SELECT trial confirmed cardiovascular benefits of Wegovy in patients with overweight/obesity and established cardiovascular disease without diabetes, leading to its 2024 FDA indication for cardiovascular risk reduction in this population

A separate 72-week trial found that obese or overweight patients using Mounjaro, the most effective weight loss injection available, lost between 15% and 20% of their body weight

By targeting these critical areas, Tirzepatide promotes weight loss, even in individuals who have struggled with weight reduction in the past

The majority of research examines therapeutic doses of 5-15mg, but there is some evidence of steady weight loss at the starter dose of 2.5mg

Its best to limit your alcohol intake while taking a GLP1 medication